Explore 3 Stock Ideas & Industry Insights Download Free Report

Mobia Medical, Inc. Common Stock

Company price
11.85 USD -0.01 ( 0.08%)
Last update at 2026-11-20T21:00:00Z
VOLUME
158925
Market Cap
358.55M

Momentum Score

…

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
11.10
Low
12.59
High
52 Week Price Range
9.85
Low
15.29
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Mobia Medical, Inc. is a Nasdaq-listed company (MOBI) with limited publicly available detail on its core operations and revenue sources. Long-term growth would depend on successful commercialization of any medical products or services, regulatory approvals, and scaling of sales and reimbursement pathways. Investors may find potential upside if management clarifies strategy and achieves commercial traction.
The most important risks are limited public disclosure and unclear revenue visibility, potential need for additional financing, regulatory and execution uncertainty, and low liquidity that could magnify share price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
11.86
Dividend Yield
-
Revenue TTM
45.28M
Revenue Per Share
6.60
Gross Profit TTM
37.02M
Debt / Equity
-0.06
ROE
-246.09%
Net Debt
-25.15M
ROCE
-119.99%
Diluted EPS TTM
-2.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Income before tax -46.49M -24.59M
Net income -46.50M -24.60M
Selling general administrative 65.83M 32.44M
Gross profit 25.98M 12.45M
Reconciled depreciation 0.15M 0.12M
Ebit -45.53M -
Ebitda -45.37M -
Depreciation and amortization 0.15M -
Operating income -46.37M -24.24M
Other operating expenses 78.41M -
Interest expense 0.97M 0.97M
Tax provision 0.01M 0.01M
Net interest income -0.97M -0.97M
Income tax expense 0.01M -
Total revenue 32.04M 15.64M
Total operating expenses 72.34M 39.88M
Cost of revenue 6.07M 3.19M
Total other income expense net -0.12M 0.62M
Net income from continuing ops -46.50M -24.60M
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total assets 48.15M 22.09M
Other current assets 2.88M 0.30M
Total liab 198.92M 128.13M
Total stockholder equity -150.77M -106.04M
Other current liab 7.63M 0.50M
Common stock 0.01M -
Capital stock 0.01M 0.01M
Retained earnings -157.79M -111.29M
Cash 33.59M 14.62M
Total current liabilities 10.21M 4.60M
Net debt -25.15M -
Short term debt 0.36M -
Short long term debt total 8.44M -
Other stockholder equity 7.01M -
Total current assets 46.36M 21.17M
Net receivables 4.44M 2.83M
Long term debt 7.13M 7.09M
Inventory 5.46M 3.43M
Accounts payable 2.22M 1.14M
Non currrent assets other 0.05M 0.02M
Non current assets total 1.79M 0.92M
Capital lease obligations 1.31M 0.63M
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total cashflows from investing activities -0.36M -
Total cash from financing activities 65.03M 15.66M
Net income -46.50M -24.60M
Change in cash 18.97M -8.70M
Begin period cash flow 14.62M 23.32M
End period cash flow 33.59M 14.62M
Total cash from operating activities -45.69M -24.32M
Issuance of capital stock 64.71M 14.99M
Depreciation 0.15M 0.12M
Change to inventory -2.03M -0.25M
Change to account receivables -1.61M -1.39M
Other cashflows from financing activities 64.71M -
Capital expenditures 0.36M 0.04M
Change in working capital -0.92M -0.63M
Stock based compensation 1.45M 0.76M
Other non cash items 0.13M 0.04M
Free cash flow -46.06M -24.36M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
MOBI
Mobia Medical, Inc. Common Stock
-0.01
0.08%
11.85 - - 7.92 1.94 3.65
ABT
Abbott Laboratories
-0.20
0.19%
103.00 25.97 17.24 3.57 3.20 3.81
MDT
Medtronic PLC
-0.59
0.59%
100.02 26.60 15.87 3.35 2.08 3.90
SYK
Stryker Corporation
-
-%
310.00 29.23 16.86 4.18 4.51 4.63
SEMHF
Siemens Healthineers AG
-
-%
48.34 39.57 21.32 3.01 3.29 2.95

Profile*

Mobia Medical, Inc. Common Stock

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.

2802 Flintrock Trace, Austin, TX, United States, 78738

(855) 628-9375

167

Name Title Year Born
Mr. Richard John Foust CEO, President & Director 1974
Mr. Thomas Jordan Curnes II, M.B.A. Co-Founder 1979
Mr. Nelson Bunker Curnes Chief Financial Officer 1983
Mr. Prashant B. Rawat Chief Operating Officer 1974
Mr. Douglas T. Ellison Chief Commercial Officer 1963
Dr. Navzer Engineer M.D., Ph.D. Co-Founder & Chief Scientific Officer NA
Mr. Chase C. Leavitt J.D. General Counsel & Corporate Secretary 1982
Mr. Philip B. Freed Vice President of Marketing NA
Ms. Steffanie Cook Vice President of Human Resources NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…